Patients in all phases of multiple sclerosis are evaluated and treated in both ambulatory and inpatient settings. Approximately 300 new patient evaluations for multiple sclerosis are performed annually. In addition, patients with myasthenia gravis, the Lambert-Eaton myasthenic syndrome, Guillain-Barre syndrome, chronic demyelinating polyneuropathy, sarcoidosis, neuroBehcet's disease, paraneoplastic syndromes, vasculitides, inflammatory myopathies and other neuroimmunologic disorders are assessed and managed.
State-of-the-art facilities and equipment are available for diagnostic studies and treatment. Cranial and spinal magnetic resonance imaging, MR spectroscopy, the full range of clinical neurophysiologic testing, conventional and special tests on cerebrospinal fluid and other laboratory methods are utilized.
Treatments offered consist of glucocorticoids, immunomodulatory agents, immunosuppressants, intravenous immunoglobulin, and therapeutic plasma exchange (plasmapheresis). Symptomatic management options such as intrathecal baclofen therapy and Botox treatment are also available.